Pfizer Inc. v. Mylan Inc.
1:09-cv-00441
Overview
Parties
Defendant
Matrix Laboratories Inc. Operating Company
Represented By
3 Attorneys ListedPlaintiff
Counter Claimant
Mylan Inc. Operating Company
Represented By
3 Attorneys ListedCounter Defendant
Matrix Laboratories Limited NPE (University / Research)
Represented By
3 Attorneys ListedCourt & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 3 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 5,969,156 A Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 145295 P | US Continuation / Sibling | View Official Patent → |
| 🌐 PCT International (WIPO) | WO 1997003959 A1 | PCT World Application | View Official Patent → |
Pfizer Inc. v. Dr. Reddy's Laboratories Ltd.
Pfizer Inc v. Ranbaxy Laboratories Limited
Patents Involved
There are 3 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US5969156
Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
|
Filed: 1996-07-08
Issued: 1999-10-19
|
Expired (Term Ended)
Expires: 2016-07-08
|
|
|
US6087511
Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
|
Filed: 1996-07-16
Issued: 2000-07-11
|
Expired (Term Ended)
Expires: 2016-07-16
|
|
|
US6274740
Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethy)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
|
Filed: 2000-09-07
Issued: 2001-08-14
|
Expired (Term Ended)
Expires: 2020-09-07
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
15
Dispositive
0
Granted
0
Denied
0
Pending / Review
15
Motions by Category
Key Dispositive Motions & Rulings